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Hyperphosphorylation of tau at multiple sites has been implicated in the formation of neuroﬁbrillary tangles
in Alzheimer’s disease; however, the relationship between toxicity and phosphorylation of tau has not been
clearly elucidated. Putative tau kinases that play a role in such phosphorylation events include the proline-
directed kinases glycogen synthase kinase-3b (GSK-3b) and cyclin-dependent kinase 5 (Cdk5), as well as
nonproline-directed kinases such as microtubule afﬁnity-regulating kinase (MARK)/PAR-1; however, whether
the cascade of events linking tau phosphorylation and neurodegeneration involves sequential action of
kinases as opposed to parallel pathways is still a matter of controversy. Here, we employed a well-
characterized Drosophila model of tauopathy to investigate the interdependence of tau kinases in regulating
the phosphorylation and toxicity of tau in vivo. We found that tau mutants resistant to phosphorylation by
MARK/PAR-1 were indeed less toxic than wild-type tau; however, this was not due to their resistance to phos-
phorylation by GSK-3b/Shaggy. On the contrary, a tau mutant resistant to phosphorylation by GSK-3b/
Shaggy retained substantial toxicity and was found to have increased afﬁnity for microtubules compared
with wild-type tau. The ﬂy homologs of Cdk5/p35 did not have major effects on tau toxicity or phosphoryl-
ation in this model. These data suggest that, in addition to tau phosphorylation, microtubule binding plays
a crucial role in the regulation of tau toxicity when misexpressed. These data have important implications
for the understanding and interpretation of animal models of tauopathy.
INTRODUCTION
The microtubule-binding protein tau is a component of neuro-
ﬁbrillary tangles (NFT) in Alzheimer’s disease (AD) and
related disorders that are collectively referred to as tauopathies
(1,2). Tau in NFT is hyperphosphorylated and it is widely
believed that the pathological action of tau kinases such as
glycogen synthase kinase-3b (GSK)-3b, microtubule afﬁnity-
regulating kinase (MARK) and cyclin-dependent kinase 5
(Cdk5) plays a role in the formation of insoluble tau aggre-
gates and NFT (3,4).
The host of kinases that phosphorylate tau in vivo can be
divided into two main groups: the proline-directed protein
kinases (PDPKs) and nonproline-directed protein kinases
(NPDPKs), depending on the residues modiﬁed. PDPKs
include GSK-3b, mitogen-activated protein kinase (ERK1/2),
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protein kinases Cdk5 and Cdc2 (5–16). NPDPKs include
cyclic AMP-dependent protein kinase A, MARK and casein
kinase II (12,17–20).
We and others have utilized the model organism
Drosophila melanogaster to model tauopathies (21–23). Direct
misexpression of wild-type human tau in the ﬂy retina resulted
in early onset cell death in the larval eye disc, as evidenced by
the formation of lamin-containing aggregates, a characteristic
ofcaspase-dependentcelldeath(21).Intheadult,neurodegenera-
tion was manifest as a ‘rough’ eye phenotype with disordered
ommatidia and bristle abnormalities; internal retinal architecture
showed polarity defects and loss of photoreceptor neurons. We
demonstrated that phosphorylation of wild-type human tau by
Shaggy, the single ﬂy homolog of GSK-3b, results in its phos-
phorylation and formation of NFT (21). Others have highlighted
the role of PAR-1, the ﬂy homolog of MARK (24), in the regu-
lation of tau toxicity (25). A mutant tau construct resistant to
PAR-1phosphorylationhasbeenshowntobelesstoxicthanwild-
typetau,suggestingarelativelymoreimportantroleforPAR-1in
determining tau toxicity compared with GSK-3b (25). More
recently,othershavesuggestedthattauthatcannotbephosphory-
lated is rendered nontoxic; nonetheless, the identiﬁcation of the
speciﬁc phosphorylation sites that regulate toxicity has proved
elusive (26,27).
Here, we set out to examine the relative importance of tau
phosphorylation by GSK-3b/Shaggy, MARK/PAR-1 and
Cdk5 in the regulation of tau phosphorylation, toxicity and
solubility. Although tau resistant to phosphorylation by
PAR-1 is less toxic than wild-type tau, this is not related to
its resistance to be subsequently phosphorylated by Shaggy.
On the other hand, tau that is resistant to phosphorylation by
Shaggy retains toxicity. Cdk5 does not play a major role in
tau phosphorylation or toxicity in our model system. The tox-
icity of tau constructs appears to be closely related to their afﬁ-
nity for microtubules, suggesting that the gain of function
phenotypes obtained by tau overexpression are related most
strongly to microtubule-based transport. These studies have
important implications for the development and interpretation
of animal models of tauopathy.
RESULTS
Misexpression of PAR-1 but not Shaggy produces
neurodegeneration
Drosophila PAR-1 and Shaggy were expressed using the
binary GAL4/UAS system with the pan-retinal GMR-GAL4
driver. Compared with the driver-alone control (Fig. 1A),
the eyes misexpressing PAR-1 (Fig. 1B) displayed a
reduced, rough-eye phenotype with disordered ommatidia
and missing bristles. Transgenics misexpressing Shaggy, on
the other hand, displayed an eye phenotype more similar to
the control (Fig. 1C). Compared with transgenics misexpres-
sing PAR-1, the eyes of transgenics misexpressing Shaggy
had a larger and more uniform appearance. In order to
compare the internal retinal morphology, confocal imaging
of adult retinas stained with TRITC-phalloidin was performed.
Tangential optical sections revealed a near-normal trapezoidal
array of rhabdomeres in the driver-alone controls (Fig. 1D). In
contrast, PAR-1 produced disorganized ommatidia with
marked disorganization of photoreceptor neurons (Fig. 1E).
The retinas of transgenics misexpressing Shaggy (Fig. 1F)
showed a relatively normal array of rhabdomeres other than
some abnormal polarity.
We and others have shown that the expression of wild-type
human tau in ﬂy photoreceptor neurons causes marked neuro-
degeneration (21,28) and suggested that this neurodegenera-
tion is linked to tau phosphorylation. We further evaluated
two important serine/threonine kinases, PAR-1 and Shaggy,
which are known to phosphorylate tau at multiple sites. In
order to study the interaction of tau with these two kinases
in more detail, we engineered two different tau substrates,
Tau
S2A and Tau
S11A, which included mutations in the major
PAR-1 and Shaggy phosphorylation sites, respectively. The
two main PAR-1 phosphorylation sites are serines 262 and
356, both of which are located in the microtubule-binding
region of tau (Fig. 2). This tau substrate has no accessible
PAR-1 phosphorylation sites but can, in theory, be phosphory-
lated by Shaggy. The second tau substrate was constructed in
which 11 of 14 major serine/threonine Shaggy phosphoryl-
ation sites were mutated to alanine. This particular substrate,
Tau
S11A, was designed so that it would be phosphorylated
by PAR-1 but resistant to Shaggy-induced phosphorylation
at the AT8, AT180, PHF1 and AT100 epitopes.
Wild-type tau is more toxic than S2A tau in the ﬂy eye
As a ﬁrst step toward elucidating the relative importance of
PAR-1 and Shaggy on tau toxicity and phosphorylation, we
Figure 1. Misexpression of PAR-1 (68) using GMR-GAL4 produces a rough
eye with the disruption of retinal architecture, whereas Sgg (63) misexpression
produces a relatively normal eye. (A–C) SEM images. The normal-eye pheno-
type observed using the GMR-GAL4 driver (A) is disrupted in eyes mis-
expressing PAR-1 (B) but not in eyes misexpressing Shaggy (C). (D–F)
Retinal whole mounts stained with phalloidin-TRITC to identify rhabdomeres
of photoreceptor neurons (single tangential confocal sections). At this apical
section, normally, clusters of seven photoreceptors within each ommatidium
form a characteristic chevron-shaped structure (D). Full genotypes:
(i) w
1118, GMR-GAL4/þ (A and D); (ii) w
1118, GMR-GAL4/þ, UAS-
PAR-1/þ (B and E); (iii) w
1118, GMR-GAL4/þ, UAS-Sgg/þ (C and F).
Scale bars: 100 mm (A–C); 10 mM (D–F).
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wild-type and S2A tau transgenes alone. Compared with
the driver-alone control, wild-type tau produced a reduced,
rough-eye phenotype (Fig. 3A). SEM analysis revealed
fused and disordered ommatidia with missing and irregular
bristles. In contrast to wild-type tau, the eyes misexpressing
Figure 2. Schematic representation of the tau constructs used. Tau
S2A was constructed by mutating two serine residues (S262 and S356) to alanine; these are the
phosphoepitopes recognized by the 12E8 antibody. Tau
S11A has 11 serine and threonine residues mutated to alanine. The epitopes recognized by
phosphorylation-dependent antibodies, e.g. AT8, AT180, PHF1 and AT100, are shown. GMR-GAL4 driver was used to drive combinations of UAS-Tau
wt,
UAS-Tau
S2A and UAS-Tau
S11A along with PAR1 and Shaggy. gl drivers were also used for the same purpose.
Figure 3. The retinal phenotype of wild-type tau (Tau
wt) under the control of GMR-GAL4 is more severe than that of S2A tau. (A and B) SEM images. The mild
rough-eye phenotype produced by Tau
wt (A) is not observed with Tau
S2A (B). Scale bars: 100 mm. (C and D) Confocal images of adult retina stained with
TRITC-phalloidin (red). Ommatidial disorganization and cell loss are apparent in the eyes overexpressing the Tau
wt transgene (C) compared with eyes expressing
Tau
S2A (D), which displays a largely normal trapezoidal array of rhabdomeres. Genotypes: (i) GMR-GAL4/þ, UAS-Tau
wt/þ (A and C); (ii) GMR-GAL4/þ,
UAS-Tau
S2A/þ (B and D). (E) Immunoblot using T46 demonstrates that several independently derived Tau
wt and Tau
S2A lines express comparable amounts
of total tau protein. b-Tubulin-loading control for total protein in head extracts is shown below. Scale bars: 100 mm (A and B); 10 mm (C and D).
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(Fig. 3B). Although mild bristle abnormalities were apparent
using SEM, the eyes were larger compared with wild-type
tau, with relatively normal ommatidia. Thus, S2A Tau was
less toxic compared with wild type. This relatively normal-eye
phenotype was observed for several independently derived
UAS-Tau
S2A lines. We also generated direct fusion gl-Tau
S2A
lines, which also consistently had more normal phenotypes
compared with those derived using wild-type tau (Supplemen-
tary Material, Fig. S1). We further examined retinal mor-
phology using confocal imaging of adult retina stained with
TRITC-phalloidin. Those retinas expressing wild-type tau
showed marked ommatidial disorganization and cell loss
(Fig. 3C), whereas S2A had a much more modest effect on
retinal morphology (Fig. 3D) and resembled the driver
control (Fig. 1D).
Given the dramatically different phenotypes produced by
wild-type and S2A tau, we compared the expression of the
transgenes using two independently derived wild-type
(Tau
wt-1 and Tau
wt-2) and three different S2A tau lines
(Tau
S2A-1, Tau
S2A-2 and Tau
S2A-3) by immunoblotting using
the T46 monoclonal antibody. Tau expression appeared to
be similar between the two genotypes (Fig. 3E).
S2A but not wild-type tau is resistant to PAR-1-induced
phosphorylation
PAR-1 has been suggested to play a central role in regulating
tau phosphorylation and toxicity (25). However, Lu and col-
leagues did not extensively evaluate effects of PAR-1 coex-
pression on wild-type and S2A tau. We directly compared
effects of PAR-1 misexpression on wild-type and S2A tau.
Figure 4. S2A is less toxic than wild-type Tau and relatively resistant to PAR-1-induced phosphorylation. (A–D) SEM images. The rough-eye phenotype of
transgenics misexpressing Tau
wt (A) is severely enhanced when coexpressed with PAR-1 (B), whereas the phenotype of Tau
S2A (C) is only mildly enhanced
by PAR-1 overexpression (D). (E–H) Phalloidin-TRITC staining of whole-mount retina. Tau
S2A (G) is less toxic than Tau
wt (E), and the enhancement in
response to PAR-1 is less severe in Tau
S2A (H) compared with Tau
wt (F). Genotypes: (i) GMR-GAL4/þ, UAS-Tau
wt/þ (A and E); (ii) GMR-GAL4/þ,
UAS-Tau
wt/þ, UAS-PAR-1/þ (B and F); (iii) GMR-GAL4/þ, UAS-Tau
S2A/þ (C and G); (iv) GMR-GAL4/þ, UAS-Tau
S2A/þ, UAS-PAR-1 (D and H).
Scale bars: 100 mm (A–D); 10 mm( E–H). (I) Immunoblot analysis with 12E8 detects stronger immunoreactivity with Tau
wt compared with Tau
S2A.( J) Histo-
grams representing relative phosphorylation level changes after the coexpression of PAR-1 and Shaggy. Results shown are derived from densitometric analysis of
three separate blots. Each bar represents mean+SEM (n ¼ 3).  P , 0.05;   P , 0.01 (ANOVA with the Newman–Keuls post hoc comparison).
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was stronger when PAR-1 was coexpressed (Fig. 4B); the mild
disorganization of the retina observed in wild-type tau eyes
was dramatically increased, resulting in smaller eyes with
more missing bristles and fused ommatidia. We note,
however, that this may be an additive rather than a synergistic
effect. When S2A was coexpressed with PAR-1 (Fig. 4D),
there was only a modest worsening of the rough-eye pheno-
type compared with transgenics overexpressing S2A tau
alone (Fig. 4C); the dual S2A/PAR-1 transgenics had slightly
more irregular eyes with disordered and occasional missing
bristles. Confocal analysis of adult retina revealed abnormal-
ities of ommatidial polarity and rhabdomere loss with wild-
type tau alone (Fig. 4E); these became more severe when
PAR-1 was coexpressed (Fig. 4F). Compared with transgenics
of the wild-type tau data set, the internal retinal morphology of
ﬂies coexpressing S2A tau and PAR-1 was only slightly worse
than that of S2A tau alone, with slightly misshapen rhabdo-
meres and a moderate loss of photoreceptor neurons (Fig. 4H).
Given that tau toxicity has been proposed to depend largely,
if not entirely, on its propensity for phosphorylation (26,27),
immunoblot analysis was performed using the 12E8 antibody,
which detects tau phosphorylated at serine 262 and 356 resi-
dues, the two sites phosphorylated by PAR-1 in the
microtubule-binding domains. As predicted, 12E8 immuno-
reactivity was increased in ﬂies expressing both wild-type
tau and PAR-1 compared with wild-type tau alone (Fig. 4I)
or coexpressed with Shaggy. On the other hand, S2A tau
ﬂies displayed minimal 12E8 signal, which did not increase
when PAR-1 was coexpressed. Quantitative analysis from
three separate experiments revealed that the 12E8 intensity
increased 1.7-fold in animals coexpressing wild-type tau and
PAR-1 compared with transgenics overexpressing wild-type
tau only (Fig. 4J). S2A tau, on the contrary, displayed no sig-
niﬁcant increase in 12E8 signal with kinase coexpression, con-
sistent with the assertion that S2A tau is resistant to
phosphorylation by PAR-1.
S2A tau is resistant to Shaggy-induced phenotypic
enhancement but not phosphorylation
Another major source of tau phosphorylation in the brain is the
proline-directed serine/threonine kinase, GSK-3b, the mam-
malian homolog of Drosophila Shaggy. As a next step, we
evaluated phosphorylation and toxicity of wild-type and S2A
tau transgenics coexpressed with Shaggy. The coexpression
of Shaggy with wild-type tau produced a markedly reduced
eye with abnormally fused ommatidia and complete loss of
bristles (Fig. 5B), similar to our ﬁndings using a slightly
different expression system (21). In contrast, the ﬂies coex-
pressing S2A Tau and Shaggy displayed more normally
sized eyes (Fig. 5D) with better organized ommatidial arrays
and bristles. The internal retinal architecture of dual wild-type
Tau/Shaggy transgenics was severely disrupted (Fig. 5F) com-
pared with wild-type tau alone (Fig. 5E), whereas the animals
coexpressing S2A tau and Shaggy displayed near-normal
retinal morphology (Fig. 5H) compared with transgenics over-
expressing S2A tau alone (Fig. 5G).
We then sought to correlate retinal phenotypes with abnor-
mal modiﬁcations of tau as assessed by phosphorylation at
AD-relevant epitopes known to be preferentially phosphory-
lated by GSK-3b (29). These are sites known to be phosphory-
lated in paired helical ﬁlamentous form of tau, and they are
detected by well-characterized antibodies, including AT8,
AT100, PHF-1 and AT180. As expected, compared with wild-
type tau alone, we observed a moderate increase in immunor-
eactivity at these epitopes in transgenics coexpressing wild-
type tau and Shaggy (Fig. 5I). Quantitative analysis of three
separate experiments revealed increases of 3-fold in the case
of AT8 and 1.5-fold in the case of PHF-1 phosphoepitopes
when wild-type tau and Shaggy were coexpressed (Fig. 5J).
In contrast to the wild-type tau data set, the basal phosphoryl-
ation of S2A Tau was scarcely detectable; however, when S2A
tau was coexpressed with Shaggy, there was a dramatic
increase in the level of phosphorylation at these particular
phosphoepitopes. Quantitative analysis from three separate
experiments displayed a relative enhancement of 9-fold and
6-fold at the AT8 and PHF-1 phosphoepitopes, respectively,
compared with wild-type tau data set (Fig. 5J). A similar
enhancement in phosphorylation level was observed for S2A
Tau and Shaggy at the AT100 epitope (Fig. 5I; Supplementary
Material, Fig. S2A and B). These data were somewhat per-
plexing given the more dramatic increases at these particular
epitopes when Shaggy was coexpressed with S2A compared
with when it was coexpressed with wild-type tau. We also
probed the level of activated Shaggy (phosphotyrosine 214,
corresponding to residue 216 of GSK-3b) for all genotypes
and observed elevated immunoreactivity in dual S2A Tau/
Shaggy transgenics compared with wild-type tau/Shaggy
animals (Supplementary Material, Fig. S2C). Intriguingly,
despite displaying dramatically elevated phosphorylation at
GSK-3b-relevant epitopes, the external eye phenotypes and
internal retinal morphology of dual S2A Tau/Shaggy trans-
genics were relatively normal. Hence, tau phosphorylation
may be only one factor underlying tau toxicity in this experi-
mental paradigm.
Dissociation of toxicity and phosphorylation of a
Shaggy-resistant mutant tau construct
Phenotypes of the direct fusion wild-type tau data set
(Fig. 6A–F) matched the data set obtained using
GMR-GAL4/UAS-Tau coexpressed with PAR-1 and Shaggy
(Figs 4 and 5). SEM analysis of the S11A animals showed
reduced, rough eyes with fused ommatidia and missing bristles
(Fig. 6G). This rough-eye phenotype was more severe when
PAR-1 was also expressed, resulting in a reduction of the
S11A eye size (Fig. 6H). However, when Shaggy was coex-
pressed with S11A tau, the eye phenotype was also enhanced
(Fig. 6I). Internal retinal morphology of the S11A tau trans-
genics was moderately abnormal (Fig. 6J), whereas retinas
from transgenics coexpressing S11A tau and PAR-1 revealed
dramatic disruption (Fig. 6K). In the case of dual S11A tau/
Shaggy transgenics, rhabdomeres showed disorganization
with some photoreceptor loss (Fig. 6L).
We then sought to determine whether the relationships
between the eye phenotypes produced by S11A tau correlated
with their phosphorylation. Immunoblotting using 12E8
revealed a strong signal in dual S11A/PAR-1 eyes; thus,
these eye phenotypes correlated with phosphorylation for
168 Human Molecular Genetics, 2009, Vol. 18, No. 1S11A/PAR-1. However, S11A tau showed no immunoreactiv-
ity at AT8, PHF-1 or AT180 epitopes under basal or stimu-
lated conditions (Fig. 6M). Thus, tau toxicity is not
determined solely by phosphorylation.
Misexpression of Drosophila Cdk5/p35 does not
modulate tau phenotypes
In order to elucidate the basis of S11A tau toxicity despite its
resistance to phosphorylation by Shaggy, we tested the effects
of another proline-directed serine/threonine kinase, Cdk5,
which also is thought to play a role in tau hyperphosphoryla-
tion (30,31). Cdk5 is present in an active form in postmitotic
neurons, where it remains associated with its regulator p35
(32). Cdk5/p35 is known to play an important role in neurite
outgrowth during neuronal differentiation and also acts as a
tau kinase. Under pathological conditions, p35 is thought to
be proteolytically cleaved to p25, which then associates with
Cdk5 to phosphorylate tau. We examined whether the coex-
pression of Cdk5 and p35 with wild-type, S2A and S11A
Figure 5. Tau
S2A is relatively resistant to Shaggy-induced toxicity but not phosphorylation. (A–D) SEM images. The rough-eye phenotype of Tau
wt (A) is
enhanced by the coexpression of Shaggy (B). The normal eye phenotype of TauS2A (C) remains unchanged when coexpressed with Shaggy (D). (E–H) Phal-
loidin staining. Shaggy expression enhances the phenotype of Tau
wt (F) but not Tau
S2A (H). Genotypes: (i) GMR-GAL4/þ, UAS-Tau
wt/þ (A and E);
(ii) GMR-GAL4/þ, UAS-Tau
wt/þ, UAS-Sgg/þ (B and F); (iii) GMR-GAL4/þ, UAS-Tau
S2A/þ (C and G); (iv) GMR-GAL4/þ, UAS-Tau
S2A/þ, UAS-Sgg
(D and H). Scale bars: 100 mm (A–D); 10 mm (E–H). (I) Immunoblot analysis shows that priming of tau by PAR-1 is not required for subsequent phosphoryl-
ation by overexpressed Sgg. The magnitude of the increase in phosphorylation at the AT8 and PHF-1 epitopes when stimulated by Sgg is greater for Tau
S2A than
for Tau
wt.( J) Histograms show relative effects on phosphorylation derived from densitometric analysis of three separate blots. Each bar represents mean+SEM
(n ¼ 3).  P , 0.05;   P , 0.01 (ANOVA with the Newman–Keuls post hoc comparison).
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failed to identify substantial effects of Cdk5/p35 on the eye
phenotypes produced by these different forms of tau (Sup-
plementary Material, Fig. S3). Immunoblotting with AT8
and PHF-1 showed no effect of Cdk5/p35 on wild-type or
S2A Tau transgenics. Basal or enhanced level of immuno-
reactivity was not detected in S11A transgenics at these phos-
phoepitopes. However, there was a modest Cdk5/p35-induced
increase in AT270 immunoreactivity antibody for S11A tau
compared with wild-type tau and S2A tau. Thus, Cdk5/p35
Figure 6. Tau
S11A retains toxicity despite being resistant to phosphorylation by Sgg. (A–C) and (G–I) SEM images. Direct fusion of gl-Tau
wt (A–C) and
gl-Tau
S11A (G–I) phenotypes is shown. Tau
S11A retains toxicity as evidenced by a severe rough-eye phenotype with disordered ommatidial morphology (G).
However, the degree of enhancement by Sgg (I) is less than that observed with wild-type Tau (C). Scale bar: 100 mm. (D–F) and (J–L) TRITC-phalloidin
staining indicates that Tau
S11A (J) retains some toxic effects on ommatidial morphology, although the response to Shaggy (L) is blunted compared with
Tau
wt. Scale bars: 100 mm (A–C and G–I); 10 mm (D–F and J–L). Genotypes: (i) GMR-GAL4/þ, gl-Tau
wt/þ (A and D); (ii) GMR-GAL4/þ, gl-Tau
wt/þ,
UAS-PAR-1/þ (B and E); (iii) GMR-GAL4/þ, gl-Tau
wt/þ, UAS-Sgg/þ (C and F); (iv) GMR-GAL4/þ, gl-Tau
S11A/þ (G and J); (v) GMR-GAL4/þ,
gl-Tau
S11A/þ, UAS-PAR-1/þ (H and K); (vi) GMR-GAL4/þ, gl-Tau
S11A/þ, UAS-Sgg/þ(I and L). (M) Immunoblot analysis showing decreased basal and
induced phosphorylation at AT8, PHF1, AT180 and AT100 phosphoepitopes for Tau
S11A compared with Tau
wt. Results obtained using the direct fusion
gl-Tau construct in combination with GMR-GAL4 driving UAS-kinases in this ﬁgure differ somewhat from those in which GMR-GAL4 drives both tau and
kinases owing to less ampliﬁcation of Tau expression in the former case, i.e. greater tau expression is achieved when glass drives GAL4 expression, which
drives Tau. This difference results in a lower ratio of Tau to kinase when gl-Tau is used.
170 Human Molecular Genetics, 2009, Vol. 18, No. 1does not appear to play a substantial role in mediating tau
toxicity in the ﬂy eye compared with PAR-1 or Shaggy;
moreover, the ability of S11A tau to produce abnormal
retinal phenotypes despite being resistant to Shaggy-induced
phosphorylation is unlikely to be due to responses to Cdk5.
Toxicity of S11A tau is not due to phosphorylation
or oxidative stress
Further experiments were carried out to analyze additional
factors that might contribute to the retinal neurodegeneration
induced by S11A compared with wild-type and S2A tau.
Thr181, which is phosphorylated by GSK-3b and found in
PHF, has not been mutated in the S11A tau construct. This
residue did not appear to contribute substantially to S11A toxi-
city, however; immunoreactivity for phosphorylated Thr181
was indistinguishable in the three transgenic lines (Sup-
plementary Material, Fig. S4). The lower mobility shift
observed in the S11A band compared with wild-type and
S2A tau arises due to the lack of phosphorylation by endogen-
ous Shaggy at the mutated serine and threonine residues.
We then evaluated the total endogenous level of some puta-
tive tau kinases along with their active forms. Although thus
far we have found no evidence for Shaggy or Cdk5 phos-
phorylation of S11A tau, it remains possible that dysregulation
of these kinases could in some way contribute toward S11A
toxicity. The total levels of endogenous Cdk5 and Shaggy
were indistinguishable between wild-type, S2A and S11A
tau. Moreover, there was no change in the active form of
Cdk5 at Tyr (15); however, interestingly, there was a
marked increase in the level of activated Shaggy (i.e.
Shaggy Y
214) (Supplementary Material, Fig. S4). An increase
in the activated form of GSK-3b could contribute toward pro-
miscuous phosphorylation of other substrates, thereby
indirectly mediating S11A tau-induced toxicity.
We further examined JNK signaling, which occurs as a con-
sequence of oxidative stress in a related model of tauopathy
(33). However, endogenous JNK expression was similar in
wild-type, S2A and S11A tau transgenic lines (Supplementary
Material, Fig. S4).
Toxicity of S11A tau is not due to formation of
soluble- and insoluble-tau aggregates
We then examined sarcosyl extracts in conjunction with the
PHF-1 antibody inan effort todetermine whether the toxic phe-
notype of S11A tau was related to the formation of tau aggre-
gates. PHF-1 detects tau phosphorylated at Ser 396 and 404
epitopes in disease forms. For equivalent amounts of input tau
(Fig. 7A, upper panel), both wild-type and S2A tau formed
high molecular weight aggregates in the soluble fraction,
whereas in the insoluble fraction the tau protein detected was
monomeric (Fig. 7A, lower panel). The level of insoluble tau
wasgreaterforwild-typetaucomparedwithS2A.Noimmunor-
eactivity was detected for S11A tau in either the soluble or the
insoluble fraction. In an independent immunoblot, sarcosyl-
soluble and -insoluble fractions were tested using the T46 anti-
body, which detects total tau (Fig. 7A, middle panel). S11A
displayed much less immunoreactivity in the soluble fraction
and no immunoreactivity in the insoluble fraction compared
with wild-type and S2A tau. Thus, the retained toxicity of
S11A tau is not due to the formation of aggregates.
Microtubule binding of S2A tau is reduced, whereas that
of S11A is increased compared with wild-type tau
One of the important physiological functions of the tau protein
is to promote the assembly and stabilize the structure of
Figure 7. Toxicity of S11A and lack of effects of S2A tau correlate not with
the formation of sarcosyl-soluble and -insoluble tau fractions, but with micro-
tubule afﬁnity. (A) Sarcosyl extracts of wild-type, S2A and S11A tau probed
with T46 (total tau) and PHF-1 (a pathological phosphoepitope). Upper panel,
input tau for the sarcosyl extraction; middle panel, sarcosyl-soluble and
-insoluble fractions probed with T46 (total tau); lower panel, pellets and super-
natants probed with PHF-1 (a pathological phosphoepitope). Tau
S11A does not
form any soluble or insoluble aggregates compared with wild-type tau,
whereas for Tau
S2A, the amount of insoluble material is much less compared
with wild-type Tau. (B) Microtubule-binding assays. Upper panel, input tau
for the microtubule-binding studies; middle panel, free or microtubule-bound
tau. Compared with wild-type tau, Tau
S2A associates with microtubules some-
what less avidly, whereas Tau
S11A shows a markedly increased afﬁnity for
microtubules. T46 blotting indicates that the levels of input tau were the
same for all three genotypes in both sarcosyl extraction and microtubule-
binding experiments. All experiments used UAS constructs in trans to
GMR-GAL4. Histograms represent the relative levels of free and bound tau
in the supernatant (S) and pellet (P) fractions, respectively, for the three differ-
ent transgenics. Each bar represents mean+SEM (n ¼ 3).  P , 0.05 for
Tau
wt and Tau
S2A, and   P , 0.001 for Tau
S11A. (One-way ANOVA with
the Newman–Keul’s post hoc comparison).
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tested for the three different tau constructs as an additional
factor that could potentially affect tau-induced toxicity. We
carried out microtubule-binding assays for wild-type, S2A
and S11A tau by incubating equivalent amounts of input wild-
type or mutant tau (Fig. 7B, upper panel) with paclitaxel-
stabilized microtubules. Amounts of tau present in supernatant
and pellet fractions were quantitated using the T46 antibody,
recognizing total tau. Although more of the tau protein in
S2A was found in the supernatant compared with wild-type
tau, almost all of the S11A Tau remained bound to micro-
tubules and was detected in the pellet fraction (Fig. 7B,
middle panel). Quantitative analysis from three different
experiments represents the relative level of tau in the super-
natant and pellet fractions in the case of wild type, S2A and
S11A. In the case of S11A, this difference in the level of
‘free’ and ‘bound’ tau was found to be highly signiﬁcant
(P , 0.001) compared with wild type and S2A (Fig.7B,
lower panel). One theory underlying tau-associated neurode-
generation is that once hyperphosphorylated, tau detaches
from microtubules, leading to microtubule destabilization
and neurodegeneration (34,35); however, this idea has yet to
be proven in intact animal or human studies. On the other
hand, it is equally possible that abnormally high binding of
tau to microtubules causes an imbalance in the structure and
function of microtubules, thereby affecting various cellular
transport processes eventually leading to neurodegeneration.
Shaggy is more effective than PAR-1 in releasing
tau from the microtubules
Since both PAR-1 and Shaggy seem to play an important role
in affecting the physiological properties of tau, our next step
was to test the effects of the individual kinases on the
microtubule-binding properties of wild-type and S2A tau.
This experiment was done by coexpressing both PAR-1 and
Shaggy with wild-type tau and S2A. We observed that when
PAR-1 was coexpressed with wild-type tau and S2A, it was
found to exert a modest effect on wild-type tau, with partial
distribution of tau in both the supernatant and microtubule-
bound pellet fractions, and no effect on S2A. On the contrary,
the coexpression of Shaggy with wild-type tau and S2A
caused most of the tau to be present in the supernatant fraction,
unassociated with the microtubules, with very little in the
pellet fractions (Supplementary Material, Fig. S5A and B,
upper panel; one-way ANOVA with the supplementary
Newman–Keuls test). Quantitative analysis of three different
experiments reveals that when Shaggy is coexpressed with
wild-type tau and S2A, there is a signiﬁcant difference
between the relative levels of tau in the supernatant and
pellet fractions (  P , 0.001). However, the coexpression of
PAR-1 produced a signiﬁcant difference in the case of the
wild type ( P , 0.05) but not S2A (Supplementary Material,
Fig. S5A and B, lower panel). Hence we can conclude that
although both PAR-1 and Shaggy were effective in releasing
tau from microtubules, Shaggy seemed to exert stronger
effects.
A similar experiment was carried out for S11A coexpres-
sing both PAR-1 and Shaggy. Histograms obtained from
three different blots revealed that despite the upregulation of
PAR-1 and Shaggy, most of the tau in S11A was found in
the pellet fractions associated with the microtubules (Sup-
plementary Material, Fig. S6). The difference in the level of
tau in the pellet and supernatant was signiﬁcant for all three
genotypes (  P , 0.001). Since Shaggy is more effective
than PAR-1 in dislodging tau from the microtubules, it is
not surprising that in the absence of Shaggy phosphorylation,
most of the S11A tau remains tightly bound to the micro-
tubules and is detected exclusively in the pellet fraction
(Fig. 7B, middle panel). Our observations here are consistent
with a mechanism underlying S11A tau toxicity that is associ-
ated not with phosphorylation but rather with markedly
increased microtubule afﬁnity.
DISCUSSION
We have demonstrated previously that the misexpression of
wild-type tau alone induces neurodegeneration in Drosophila,
and that this phenotype is exacerbated when tau is coexpressed
with Shaggy, the single ﬂy homolog of GSK-3b (21). On the
other hand, Lu and coworkers reported that PAR-1 plays a
primary role in regulating tau-induced toxicity in the ﬂy
(25), and that phosphorylation by PAR-1 is a prerequisite for
tau to be subsequently phosphorylated by GSK-3b/Shaggy
or Cdk5. Other investigators have suggested on the basis of
ﬁndings in ﬂy models that tau-induced neurodegeneration is
caused by defects in microtubule-dependent axonal transport,
leading to a loss of synaptic transmission and vesicle aggrega-
tion in the early stages of AD (36,37); nonetheless, recent evi-
dence directly measuring axonal transport in vitro has
questioned this mechanism (38).
Although the misexpression of kinases and/or human tau in
the Drosophila eye undoubtedly causes neurodegeneration
that differs in many important respects from that occurring
in AD and related neurodegenerative tauopathies, our group
and numerous others have repeatedly demonstrated that this
model system can lead to powerful insights into pathophysio-
logical mechanisms underlying these disorders (21,25–28,39–
46). The ‘rough’ eye readout is relatively nonspeciﬁc in
models of human neurodegenerative diseases and can result
from the disruption of a host of developmental processes in
addition to cell death per se. Nonetheless, compared with
the eye phenotypes obtained in ﬂy models of Huntington’s
disease (47–51), as an example, the tau eye phenotype pro-
vides a highly sensitive and robust readout that makes it
quite useful for assessing phenotypic effects of genetic
manipulations.
Reduced toxicity in S2A compared with wild-type tau is
not due to its inability to be phosphorylated by Shaggy
Lu and colleagues have suggested that Tau
S2A, which is
resistant to PAR-1 phosphorylation, is also resistant to phos-
phorylation by Shaggy and Cdk5, implying that these proline-
directed kinases act downstream of PAR-1. We observed
that although Tau
S2A alone displayed lower immunoreactivity
at a variety of AD-related phosphoepitopes compared with
Tau
wt, there was a dramatic increase in phosphoryl-
ation when Shaggy was coexpressed with Tau
S2A (Fig. 5I).
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alent levels of endogenous Shaggy in wild-type and S2A tau
(data not shown), activated Shaggy was much higher when
Shaggy was coexpressed with Tau
S2A compared with
Shaggy coexpressed with Tau
wt (Supplementary Material,
Fig. S2C). In presenilin-1 familial AD mutations, the PI3K/
Akt pathway is inhibited, thus promoting GSK-3b activity
and tau phosphorylation, and in turn promoting tau pathology
(52). In the case of S2A tau, however, we could not correlate
this Shaggy-induced hyperphosphorylation with neurodegen-
eration, suggesting dissociation in some instances between
tau phosphorylation and neurodegeneration.
S11A is resistant to GSK-3b/Shaggy phosphorylation
but retains toxicity
We provide further evidence for dissociation between tau
phosphorylation and neurodegeneration using the construct
Tau
S11A. Using multiple different insertions and expression
systems, in several instances we observed that the external
eye phenotype of Tau
S11A data set (Fig. 6G–I) is as severe
as displayed by Tau
wt data set (Fig. 6A–C). However, immu-
noblotting using Shaggy-dependent phosphoepitope antibodies
fails to detect any signal for S11A, though both SEM analysis
of external eye phenotypes and confocal imaging of internal
retinal architecture conﬁrm substantial toxicity of this con-
struct despite its resistance to phosphorylation (Fig. 6M).
Formation of soluble and insoluble aggregates is more
pronounced in wild type and S2A compared with S11A tau
Tau is abnormally phosphorylated in AD and is the main com-
ponent of PHF and thus NFT. Biochemically, NFT can be iso-
lated on the basis of insolubility in the detergent sarcosyl (53).
Immunoblot analysis using T46 antibody that detects both
phosphorylated and unphosphorylated tau reveals that in trans-
genic Drosophila, wild-type tau is primarily sarcosyl insolu-
ble, whereas sarcosyl-soluble tau is present in all three
transgenics. Further analysis of sarcosyl fractions with PHF-1
detected no signal for Tau
S11A, whereas hyperphosphorylated
tau was localized to both soluble and insoluble fractions for
wild-type and S2A tau transgenics. It is also interesting to
note that the tau in the soluble fractions from wild-type and
S2A tau transgenics forms high molecular weight aggregates.
It is now speculated that certain soluble pathological forms of
tau may be more detrimental than insoluble forms, but
the correlation of tau aggregation and toxicity remains to be
elucidated (54).
Microtubule-binding properties of S11A are different
from wild-type and S2A tau
In the case of wild-type and S2A tau transgenics, we observed
distribution in both supernatant (unbound tau) and pellet
(bound tau) fractions, whereas for Tau
S11A almost all of the
tau was detected in the pellet bound to the microtubules.
This observation may help to explain Tau
S11A-induced toxicity
and neurodegeneration in the absence of phosphorylation. One
current hypothesis holds that the physiological function of tau
is adversely affected due to excess tau phosphorylation. This
hyperphosphorylated tau then gets displaced from the micro-
tubules, aggregates and leads to microtubule disassembly
such that axonal transport is disrupted. However, certain
observations contradict this model. Tau-deﬁcient transgenic
mice show no major phenotype (55), perhaps since tau can
be substituted for by other factors (e.g. MAP1b). Moreover,
mice misexpressing tau show transport defects even though
microtubules are intact and tau aggregates are absent
(56,57); ﬂies misexpressing tau also show defects in neuronal
trafﬁc without evidence of tau aggregation (37). These obser-
vations argue that even ‘normal’ tau may be detrimental when
its expression becomes elevated. Moreover, there are further
reports that prove that the coexpression of GSK-3b with the
longest tau isoform actually serves to reduce axonal dilations
and degeneration (58). From all these observations, it appears
that an optimal level of tau phosphorylation is required to
achieve the balance in the level of ‘free’ and ‘microtubule
bound’ tau that is essential in maintaining microtubule
dynamics and subsequent axonal transport.
PAR-1 and Shaggy act in a concerted fashion to release tau
from microtubules with a more signiﬁcant contribution
from Shaggy
The respective contributions of the kinases PAR-1 and Shaggy
toward microtubule-binding properties of tau were examined.
Both PAR1 and Shaggy are instrumental in releasing tau from
microtubules, but Shaggy is probably a more important contri-
butor in this respect. In the case of Tau
S11A, since most Shaggy
phosphorylation sites have been mutated, this form of tau may
be irreversibly bound to microtubules, disrupting axonal trans-
port and resulting in subsequent neurodegeneration.
Perspectives on the relationship between tau
phosphorylation and toxicity in the context
of animal models
Other recent work using a related Drosophila model of tauo-
pathy has suggested that the phosphorylation of tau is the
sine qua non for its toxicity (27). This observation was
based on a tau construct which differed from the longest
isoform of human tau not only in the presence of 14 serine/
threonine residues which had been converted to alanine, but
also in that this construct lacks the amino terminal inserts gen-
erated by alternative splicing of exons 2 and 3. The discre-
pancy between the lack of toxicity of this ‘S14A’ construct
and the toxic S11A construct shown here might derive in
part from this lack of amino terminal sequences that may posi-
tively regulate aggregation (59). More recently, Feany and col-
leagues reported that although single- or double-
phosphorylation mutants did not appreciably alter toxicity
compared with wild-type tau, one mutant consisting of ﬁve
altered residues [Ser202/Thr205 (AT8), T212 (part of
AT100) and T231/S235] did not exhibit substantially lower
toxicity compared with wild-type tau (26). Whether this con-
struct exhibited increased microtubule afﬁnity as we observed
for S11A tau transgenic was not reported. The most recent
data of Feany and colleagues do, however, agree with our
hypothesis that although tau phosphorylation, all other things
being equal, does play a permissive role in neurodegeneration,
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Recently Nixon and colleagues directly measured axonal
transport in the optic nerve of animals misexpressing tau and
failed to identify impairments using direct measures, as
opposed to indirect markers of axonal transport blockage
(38). Whether the toxicity of phosphorylation-resistant tau
depends on impaired axonal transport due to irreversible
microtubule binding, or possibly a nonspeciﬁc effect on
microtubules without affecting axonal transport per se,a s
has been suggested using studies of squid, remains to be deter-
mined (60). Our data do, however, suggest that multiple
factors potentially regulating tauopathy in addition to phos-
phorylation must be considered in the interpretation of
animal models of tauopathy.
In a physiological milieu, tau remains bound to micro-
tubules to maintain stability and undergoes a normal phos-
phorylation/dephosphorylation cycle so that it can transiently
come off the microtubules. This process facilitates neurite out-
growth during development, as well as axonal transport
throughout life, processes which would otherwise likely
come to a complete halt in the presence of excess tau.
Although both proline- and nonproline-directed kinases such
as GSK-3b and MARK are effective in releasing tau from
microtubules, our data suggest that the former exerts a more
robust effect overall. Any disruption of the phosphorylation/
dephosphorylation cycle can exert toxic effects on the
Drosophila eye during development. Hyperphosphorylation
of tau leads to the formation of soluble and insoluble aggre-
gates which form a hallmark lesion of AD; this form of tau
pathology is evident in the case of wild-type tau coexpressed
with PAR-1 and Shaggy. On the other hand, the inability of
tau to be phosphorylated by Shaggy can also be detrimental
for the cells since this may cause tau to irreversibly bind to
microtubules, thereby overstabilizing them and blocking cellu-
lar processes dependent upon microtubule-based transport.
This form of tau pathology has been observed in the case of
S11A tau and its coexpression with PAR-1 and Shaggy. Our
observations therefore support a model in which a delicate
balance exists between tau hyper- and hypophosphorylation,
any deviation from which may lead to toxic effects of tau.
MATERIALS AND METHODS
Constructs, genetics and stocks
The UAS-Tau
wt transgenic Drosophila lines were derived by
subcloning a cDNA encoding wild-type htau4R into the Exe-
lixis modiﬁcation (61) of the pUAST vector (62). Seven trans-
genic lines were obtained using standard techniques. Lines
were selected for use on the basis of convenience of chromo-
somal linkage; in no case were lines on the basis of strong or
weak phenotypes. We chose the UAS-Tau
wt line 11.1 on
chromosome II, which shows a moderate phenotype, for use
in the majority of our experiments. The UAS-Tau
S2A trans-
genics were derived by site-directed mutagenesis of the wild-
type tau construct to transform serines 262 and 356 to alanine.
Four such lines were obtained, of which lines 1.33 and 1.62,
both located on chromosome II, were chosen for further
study. These lines are similar to the UAS-Tau
S2A line reported
by Lu and coworkers (25) except that they are based on the
expression of the longest isoform of wild-type human tau,
rather than the FTDP-17-associated R406W mutation. The
UAS-Tau
S11A transgenics were derived using an oligonucleo-
tide encoding wild-type tau with mutations at 11 residues:
S46A, T50A, S199A, T202A, T205A, T212A, S214A,
T231A, S235A, S396A and S404A. Four lines were obtained;
we selected line 1.2 on chromosome II for most experiments.
These lines are similar to the UAS-Tau
AP lines reported by
Feany and colleagues (27) except that our S11A lines also
include the two amino terminal inserts that are generated by
alternative splicing of exons 2 and 3. Transgenic lines for
UAS-Tau
wt, UAS-Tau
S2A and UAS-Tau
S11A were matched
for equivalent levels of total tau expression by immunoblot
analysis using the T46 monoclonal antibody. UAS-Shaggy
was obtained from Siegfried (63). Lu generously supplied
the UAS-PAR1 line (25), and the UAS-Cdk5 and UAS-p35
lines were obtained from Giniger (64). The gl-Tau
S2A and
gl-Tau
S11A transgenes were obtained by subcloning the appro-
priate inserts, as described previously, into the pExpress-gl
modiﬁcation (61) of the GMR expression vector (65). Over-
expression of UAS transgenes was achieved using a relatively
weak X-linked GMR-GAL4 driver (66). Flies were grown on
standard cornmeal-based Drosophila medium at 238C.
Histology and immunohistochemistry. For SEM, ﬂies were
dehydrated in ethanol, incubated overnight in hexamethyldisi-
lazane, dried under vacuum, attached to stubs with black nail
polish and analyzed using a Hitachi SEM (21). TRITC-
phalloidin (Sigma, St Louis, MO, USA) whole-mount staining
of adult retina was carried out as described previously (48)
using a Zeiss Pascal laser scanning confocal microscope.
Immunoblotting. To analyze the phosphorylation status of tau,
freshly eclosed adult ﬂies were collected and heads were dis-
sected and homogenized in a lysis buffer consisting of Tris–Cl
(10 mM, pH 7.4), NaCl (150 mM), EDTA (5 mM), EGTA
(5 mM), glycerol (10% v/v), NaF (50 mM), Na3VOF3 (1 mM),
NaPPi (5 mM), DTT (5 mM), urea (4 M) and protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN, USA).
Extracts were mixed with SDS sample buffer, heated at
708C, centrifuged at 4000 g for 5 min and separated by 10%
SDS–PAGE. Proteins were transferred to nitrocellulose,
blocked in 5% (w/v) nonfat dried milk in Tris-buffered
saline containing 0.1% Tween 20 and immunoblotted using
the following antibodies: T46 (Invitrogen, Carlsbad, CA,
USA; 1:1000), AT8, AT180, AT270 and AT100 (Pierce
Biotechnology, Rockford, IL, USA; all used at 1:2000
except for AT100 (1:500), anti-Thr 181 (Promega, Madison,
WI, USA; 1:200), anti-active JNK (Promega, 1:500), PHF-1
(1:5000), 12E8 (1:2000), anti-Sgg/GSK-3b (clone 0.T.56;
US Biological, Swampscott, MA, USA; 1:500), anti-
GSK3bY
216 (clone 0.T.57; US Biological; 1:500; correspond-
ing to SggY
214), anti-CDK5 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA; 1:500), anti-Cdk5Y (15) (Santa Cruz; 1:500)
and anti-active JNK (Promega 1:500). The membranes were
incubated with peroxidase-labeled anti-mouse or anti-rabbit
IgG and signals were detected using chemiluminescence.
Films derived from immunoblots were scanned using a Power-
look 1000 transmissive ﬂatbed scanner (UMAX, Dallas, TX,
USA). Densities of bands were measured with NIH ImageJ
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were performed using SigmaPlot 9.0 and SigmaStat 3.1
(Systat, San Jose, CA, USA).
Microtubule-binding assay. Determination of tau binding to
exogenously added microtubules was performed according to
the manufacturer’s protocol (Cytoskeleton, Denver, CO,
USA) with some modiﬁcations (67). Whole-head extracts
were homogenized in a lysis buffer consisting of HEPES
(5 mM, pH 7.4) and NaCl (100 mM) and including protease
inhibitors. Extracts were clariﬁed with a low spin at 4000 g
for 5 min followed by a high spin of 7500 g for 20 min at 48C.
The protein content of the high-spin supernatant was determined
by the Bradford method, and extracts containing equivalent
amountoftotalproteinwereincubatedwithpaclitaxel-stabilized,
in vitro polymerized microtubules following the manufacturer’s
instruction. Following incubation, fractions were loaded onto a
50% glycerol gradient and centrifuged at 110 000 g (TLA 55)
for 45 min. The supernatant and pellet fractions were collected
and analyzed by immunoblotting with T46 to estimate the
amount of tau bound to microtubules.
Sarcosyl extraction. Fifty ﬂy heads were homogenized in
100 ml of homogenization buffer consisting of Tris–Cl
(10 mM, pH 7.4), NaCl (0.8 M), NaCl (1 mM), EGTA (1 mM)
and sucrose (10% w/v). The homogenates were centrifuged
at 21 000 g for 30 min. The supernatant was brought to 1%
N-lauroylsarcosinate and incubated 1 h at room temperature
while shaking gently. After a 1 h spin at 90 000 g at 48C,
the supernatants were collected as the sarcosyl-soluble
fraction; the sarcosyl-insoluble pellets were suspended in
Tris–Cl (50 mM) and stored at 48C. These samples were
later used for immunoblot analysis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
Thanks to Bingwei Lu, Esther Siegfried, Ed Giniger and the
Bloomington Stock Center for ﬂy strains. Thanks also to
Peter Davies and Peter Seubert for antibodies.
Conﬂict of Interest statement. None declared.
FUNDING
This work was supported by grants from the National Insti-
tutes of Health (NS046489; AG016570) and American
Health Assistance Foundation. Funding to pay the open
access charges was provided by the National Institutes of
Health.
REFERENCES
1. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M.,
Yoshida, H., Watanabe, A., Titani, K. and Ihara, Y. (1995)
Hyperphosphorylation of tau in PHF. Neurobiol. Aging, 16, 365–371.
2. Johnson, G.V. and Bailey, C.D. (2002) Tau, where are we now?
J. Alzheimers Dis., 4, 375–398.
3. Cho, J.H. and Johnson, G.V. (2003) Glycogen synthase kinase 3beta
phosphorylates tau at both primed and unprimed sites. Differential impact
on microtubule binding. J. Biol. Chem., 278, 187–193.
4. Augustinack, J.C., Schneider, A., Mandelkow, E.M. and Hyman, B.T.
(2002) Speciﬁc tau phosphorylation sites correlate with severity of
neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol. (Berl.),
103, 26–35.
5. Baum, L., Hansen, L., Masliah, E. and Saitoh, T. (1996) Glycogen
synthase kinase 3 alteration in Alzheimer disease is related to
neuroﬁbrillary tangle formation. Mol. Chem. Neuropathol., 29,
253–261.
6. Lovestone, S., Reynolds, C.H., Latimer, D., Davis, D.R., Anderton, B.H.,
Gallo, J.M., Hanger, D., Mulot, S., Marquardt, B., Stabel, S. et al. (1994)
Alzheimer’s disease-like phosphorylation of the microtubule-associated
protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
Curr. Biol., 4, 1077–1086.
7. Mandelkow, E.M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J.,
Vandenheede, J.R. and Mandelkow, E. (1992) Glycogen synthase
kinase-3 and the Alzheimer-like state of microtubule-associated protein
tau. FEBS Lett., 314, 315–321.
8. Mulot, S.F., Hughes, K., Woodgett, J.R., Anderton, B.H. and Hanger, D.P.
(1994) PHF-tau from Alzheimer’s brain comprises four species on SDS–
PAGE which can be mimicked by in vitro phosphorylation of human brain
tau by glycogen synthase kinase-3 beta. FEBS Lett., 349, 359–364.
9. Kobayashi, S., Ishiguro, K., Omori, A., Takamatsu, M., Arioka, M.,
Imahori, K. and Uchida, T. (1993) A cdc2-related kinase PSSALRE/cdk5
is homologous with the 30 kDa subunit of tau protein kinase II, a
proline-directed protein kinase associated with microtubule. FEBS Lett.,
335, 171–175.
10. Singh, T.J., Zaidi, T., Grundke-Iqbal, I. and Iqbal, K. (1995) Modulation
of GSK-3-catalyzed phosphorylation of microtubule-associated protein
tau by non-proline-dependent protein kinases. FEBS Lett., 358,4 – 8 .
11. Sperber, B.R., Leight, S., Goedert, M. and Lee, V.M. (1995) Glycogen
synthase kinase-3 beta phosphorylates tau protein at multiple sites in
intact cells. Neurosci. Lett., 197, 149–153.
12. Zheng-Fischhofer, Q., Biernat, J., Mandelkow, E.M., Illenberger, S.,
Godemann, R. and Mandelkow, E. (1998) Sequential phosphorylation of
Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212
and Ser214 generates the Alzheimer-speciﬁc epitope of antibody AT100
and requires a paired-helical-ﬁlament-like conformation.
Eur. J. Biochem., 252, 542–552.
13. Reynolds, C.H., Utton, M.A., Gibb, G.M., Yates, A. and Anderton, B.H.
(1997) Stress-activated protein kinase/c-jun N-terminal kinase
phosphorylates tau protein. J. Neurochem., 68, 1736–1744.
14. Roder, H.M., Eden, P.A. and Ingram, V.M. (1993) Brain protein kinase
PK40erk converts TAU into a PHF-like form as found in Alzheimer’s
disease. Biochem. Biophys. Res. Commun., 193, 639–647.
15. Hyman, B.T., Elvhage, T.E. and Reiter, J. (1994) Extracellular signal
regulated kinases. Localization of protein and mRNA in the human
hippocampal formation in Alzheimer’s disease. Am. J. Pathol., 144,
565–572.
16. Ledesma, M.D., Correas, I., Avila, J. and Diaz-Nido, J. (1992) Implication
of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in
Alzheimer’s disease. FEBS Lett., 308, 218–224.
17. Robertson, J., Loviny, T.L., Goedert, M., Jakes, R., Murray, K.J.,
Anderton, B.H. and Hanger, D.P. (1993) Phosphorylation of tau by
cyclic-AMP-dependent protein kinase. Dementia, 4, 256–263.
18. Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E.M. and Mandelkow, E.
(1997) MARK, a novel family of protein kinases that phosphorylate
microtubule-associated proteins and trigger microtubule disruption. Cell,
89, 297–308.
19. Jenkins, S.M., Zinnerman, M., Garner, C. and Johnson, G.V. (2000)
Modulation of tau phosphorylation and intracellular localization by
cellular stress. Biochem. J., 345, 263–270.
20. Kannanayakal, T.J., Tao, H., Vandre, D.D. and Kuret, J. (2006) Casein
kinase-1 isoforms differentially associate with neuroﬁbrillary and
granulovacuolar degeneration lesions. Acta Neuropathol., 111, 413–421.
21. Jackson, G.R., Wiedau-Pazos, M., Sang, T.K., Wagle, N., Brown, C.A.,
Massachi, S. and Geschwind, D.H. (2002) Human wild-type tau interacts
with wingless pathway components and produces neuroﬁbrillary
pathology in Drosophila. Neuron, 34, 509–519.
Human Molecular Genetics, 2009, Vol. 18, No. 1 17522. Wittmann, C.W., Wszolek, M.F., Shulman, J.M., Salvaterra, P.M., Lewis,
J., Hutton, M. and Feany, M.B. (2001) Tauopathy in Drosophila:
neurodegeneration without neuroﬁbrillary tangles. Science, 293,
711–714.
23. Williams, D.W., Tyrer, M. and Shepherd, D. (2000) Tau and tau reporters
disrupt central projections of sensory neurons in Drosophila. J. Comp.
Neurol., 428, 630–640.
24. Shulman, J.M., Benton, R. and St Johnston, D. (2000) The Drosophila
homolog of C. elegans PAR-1 organizes the oocyte cytoskeleton and
directs oskar mRNA localization to the posterior pole. Cell, 101,
377–388.
25. Nishimura, I., Yang, Y. and Lu, B. (2004) PAR-1 kinase plays an initiator
role in a temporally ordered phosphorylation process that confers tau
toxicity in Drosophila. Cell, 116, 671–682.
26. Steinhilb, M.L., Dias-Santagata, D., Fulga, T.A., Felch, D.L. and
Feany, M.B. (2007) Tau phosphorylation sites work in concert to
promote neurotoxicity in vivo. Mol. Biol. Cell., 18, 5060–5068.
27. Steinhilb, M.L., Dias-Santagata, D., Mulkearns, E.E., Shulman, J.M.,
Biernat, J., Mandelkow, E.M. and Feany, M.B. (2007) S/P and T/P
phosphorylation is critical for tau neurotoxicity in Drosophila.
J. Neurosci. Res., 85, 1271–1278.
28. Khurana, V., Lu, Y., Steinhilb, M.L., Oldham, S., Shulman, J.M. and
Feany, M.B. (2006) TOR-mediated cell-cycle activation causes
neurodegeneration in a Drosophila tauopathy model. Curr. Biol., 16,
230–241.
29. Plattner, F., Angelo, M. and Giese, K.P. (2006) The roles of
cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau
hyperphosphorylation. J. Biol. Chem., 281, 25457–25465.
30. Maccioni, R.B., Otth, C., Concha, I.I. and Munoz, J.P. (2001) The protein
kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in
Alzheimer’s pathology. Eur. J. Biochem., 268, 1518–1527.
31. Smith, D.S., Greer, P.L. and Tsai, L.H. (2001) Cdk5 on the brain. Cell
Growth Differ., 12, 277–283.
32. Tsai, L.H., Delalle, I., Caviness, V.S. Jr, Chae, T. and Harlow, E. (1994)
p35 is a neural-speciﬁc regulatory subunit of cyclin-dependent kinase 5.
Nature, 371, 419–423.
33. Dias-Santagata, D., Fulga, T.A., Duttaroy, A. and Feany, M.B. (2007)
Oxidative stress mediates tau-induced neurodegeneration in Drosophila.
J. Clin. Invest., 117, 236–245.
34. Li, B., Chohan, M.O., Grundke-Iqbal, I. and Iqbal, K. (2007) Disruption of
microtubule network by Alzheimer abnormally hyperphosphorylated tau.
Acta Neuropathol., 113, 501–511.
35. Paudel, H.K., Lew, J., Ali, Z. and Wang, J.H. (1993) Brain
proline-directed protein kinase phosphorylates tau on sites that are
abnormally phosphorylated in tau associated with Alzheimer’s paired
helical ﬁlaments. J. Biol. Chem., 268, 23512–23518.
36. Chee, F.C., Mudher, A., Cuttle, M.F., Newman, T.A., MacKay, D.,
Lovestone, S. and Shepherd, D. (2005) Over-expression of tau results in
defective synaptic transmission in Drosophila neuromuscular junctions.
Neurobiol. Dis., 20, 918–928.
37. Mudher, A., Shepherd, D., Newman, T.A., Mildren, P., Jukes, J.P.,
Squire, A., Mears, A., Drummond, J.A., Berg, S., MacKay, D. et al.
(2004) GSK-3beta inhibition reverses axonal transport defects and
behavioural phenotypes in Drosophila. Mol. Psychiatry, 9, 522–530.
38. Yuan, A., Kumar, A., Peterhoff, C., Duff, K. and Nixon, R.A. (2008)
Axonal transport rates in vivo are unaffected by tau deletion or
overexpression in mice. J. Neurosci., 28, 1682–1687.
39. Karsten, S.L., Sang, T.K., Gehman, L.T., Chatterjee, S., Liu, J.,
Lawless, G.M., Sengupta, S., Berry, R.W., Pomakian, J., Oh, H.S. et al.
(2006) A genomic screen for modiﬁers of tauopathy identiﬁes
puromycin-sensitive aminopeptidase as an inhibitor of tau-induced
neurodegeneration. Neuron, 51, 549–560.
40. Shulman, J.M. and Feany, M.B. (2003) Genetic modiﬁers of tauopathy in
Drosophila. Genetics, 165, 1233–1242.
41. Ghosh, S. and Feany, M.B. (2004) Comparison of pathways controlling
toxicity in the eye and brain in Drosophila models of human
neurodegenerative diseases. Hum. Mol. Genet., 13, 2011–2018.
42. Fulga, T.A., Elson-Schwab, I., Khurana, V., Steinhilb, M.L., Spires, T.L.,
Hyman, B.T. and Feany, M.B. (2007) Abnormal bundling and
accumulation of F-actin mediates tau-induced neuronal degeneration
in vivo. Nat. Cell Biol., 9, 139–148.
43. Dermaut, B., Norga, K.K., Kania, A., Verstreken, P., Pan, H., Zhou, Y.,
Callaerts, P. and Bellen, H.J. (2005) Aberrant lysosomal carbohydrate
storage accompanies endocytic defects and neurodegeneration in
Drosophila benchwarmer. J. Cell Biol., 170, 127–139.
44. Chen, X., Li, Y., Huang, J., Cao, D., Yang, G., Liu, W., Lu, H. and
Guo, A. (2007) Study of tauopathies by comparing Drosophila and human
tau in Drosophila. Cell Tissue Res., 329, 169–178.
45. Blard, O., Feuillette, S., Bou, J., Chaumette, B., Frebourg, T.,
Campion, D. and Lecourtois, M. (2007) Cytoskeleton proteins are
modulators of mutant tau-induced neurodegeneration in Drosophila. Hum.
Mol. Genet., 16, 555–566.
46. Chau, K.W., Chan, W.Y., Shaw, P.C. and Chan, H.Y. (2006) Biochemical
investigation of Tau protein phosphorylation status and its solubility
properties in Drosophila. Biochem. Biophys. Res. Commun., 346, 150–159.
47. Jackson, G.R., Salecker, I., Dong, X., Yao, X., Arnheim, N., Faber, P.W.,
MacDonald, M.E. and Zipursky, S.L. (1998) Polyglutamine-expanded
human huntingtin transgenes induce degeneration of Drosophila
photoreceptor neurons. Neuron, 21, 633–642.
48. Sang, T.K., Li, C., Liu, W., Rodriguez, A., Abrams, J.M., Zipursky, S.L.
and Jackson, G.R. (2005) Inactivation of Drosophila Apaf-1 related killer
suppresses formation of polyglutamine aggregates and blocks
polyglutamine pathogenesis. Hum. Mol. Genet., 14, 357–372.
49. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A.,
Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M.
et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-
dependent neurodegeneration in Drosophila. Nature, 413, 739–743.
50. Romero, E., Cha, G.H., Verstreken, P., Ly, C.V., Hughes, R.E., Bellen,
H.J. and Botas, J. (2008) Suppression of neurodegeneration and increased
neurotransmission caused by expanded full-length huntingtin
accumulating in the cytoplasm. Neuron, 57, 27–40.
51. Branco, J., Al-Ramahi, I., Ukani, L., Perez, A.M., Fernandez-Funez, P.,
Rincon-Limas, D. and Botas, J. (2008) Comparative analysis of genetic
modiﬁers in Drosophila points to common and distinct mechanisms of
pathogenesisamongpolyglutaminediseases.Hum.Mol.Genet.,17,376–390.
52. Baki, L., Shioi, J., Wen, P., Shao, Z., Schwarzman, A., Gama-Sosa, M.,
Neve, R. and Robakis, N.K. (2004) PS1 activates PI3K thus inhibiting
GSK-3 activity and tau overphosphorylation: effects of FAD mutations.
EMBO J., 23, 2586–2596.
53. Greenberg, S.G. and Davies, P. (1990) A preparation of Alzheimer paired
helical ﬁlaments that displays distinct tau proteins by polyacrylamide gel
electrophoresis. Proc. Natl Acad. Sci. USA, 87, 5827–5831.
54. Oddo, S., Caccamo, A., Cheng, D., Jouleh, B., Torp, R. and LaFerla, F.M.
(2007) Genetically augmenting tau levels does not modulate the onset or
progression of Abeta pathology in transgenic mice. J. Neurochem., 102,
1053–1063.
55. Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T.,
Sato-Yoshitake, R., Takei, Y., Noda, T. and Hirokawa, N. (1994) Altered
microtubule organization in small-calibre axons of mice lacking tau
protein. Nature, 369, 488–491.
56. Gotz, J., Chen, F., Barmettler, R. and Nitsch, R.M. (2001) Tau ﬁlament
formation in transgenic mice expressing P301L tau. J. Biol. Chem., 276,
529–534.
57. Ishihara, T., Zhang, B., Higuchi, M., Yoshiyama, Y., Trojanowski, J.Q. and
Lee, V.M. (2001) Age-dependent induction of congophilic neuroﬁbrillary
tau inclusions in tau transgenic mice. A m .J .P a t h o l . , 158, 555–562.
58. Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M.,
Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T. et al.
(2000) Glycogen synthase kinase-3beta phosphorylates protein tau and
rescues the axonopathy in the central nervous system of human
four-repeat tau transgenic mice. J. Biol. Chem., 275, 41340–41349.
59. Gamblin, T.C., Berry, R.W. and Binder, L.I. (2003) Tau polymerization:
role of the amino terminus. Biochemistry, 42, 2252–2257.
60. Morﬁni, G., Pigino, G., Mizuno, N., Kikkawa, M. and Brady, S.T. (2007)
Tau binding to microtubules does not directly affect microtubule-based
vesicle motility. J. Neurosci. Res., 85, 2620–2630.
61. Ollmann, M., Young, L.M., Di Como, C.J., Karim, F., Belvin, M.,
Robertson, S., Whittaker, K., Demsky, M., Fisher, W.W., Buchman, A.
et al. (2000) Drosophila p53 is a structural and functional homolog of the
tumor suppressor p53. Cell, 101, 91–101.
62. Brand, A.H. and Perrimon, N. (1993) Targeted gene expression as a
means of altering cell fates and generating dominant phenotypes.
Development, 118, 401–415.
63. Steitz, M.C., Wickenheisser, J.K. and Siegfried, E. (1998) Overexpression
of zeste white 3 blocks wingless signaling in the Drosophila embryonic
midgut. Dev. Biol., 197, 218–233.
176 Human Molecular Genetics, 2009, Vol. 18, No. 164. Connell-Crowley, L., Le Gall, M., Vo, D.J. and Giniger, E. (2000) The
cyclin-dependent kinase Cdk5 controls multiple aspects of axon
patterning in vivo. Curr. Biol., 10, 599–602.
65. Hay, B.A., Wassarman, D.A. and Rubin, G.M. (1995) Drosophila
homologs of baculovirus inhibitor of apoptosis proteins function to block
cell death. Cell, 83, 1253–1262.
66. Yamaguchi, M., Hirose, F., Inoue, Y.H., Shiraki, M., Hayashi, Y.,
Nishi, Y. and Matsukage, A. (1999) Ectopic expression of human p53
inhibits entry into S phase and induces apoptosis in the Drosophila eye
imaginal disc. Oncogene, 18, 6767–6775.
67. Lantz, V.A. and Miller, K.G. (1998) A class VI unconventional myosin is
associated with a homologue of a microtubule-binding protein,
cytoplasmic linker protein-170, in neurons and at the posterior pole of
Drosophila embryos. J. Cell Biol., 140, 897–910.
68. Sun, T.Q., Lu, B., Feng, J.J., Reinhard, C., Jan, Y.N., Fantl, W.J. and
Williams, L.T. (2001) PAR-1 is a dishevelled-associated kinase and a
positive regulator of Wnt signalling. Nat. Cell Biol., 3, 628–636.
Human Molecular Genetics, 2009, Vol. 18, No. 1 177